Figure 1. Rates of (A) completion lymphadenectomy, (B) chemotherapy, (C) immunotherapy, and (D) radiation therapy among stage IIIA, B and C patients by age. There were significant differences in rates of (A) completion lymphadenectomy (stage IIIA, B, & C disease, p<0.0001), (B) chemotherapy (stage IIIA, B, & C disease, p<0.0001), (C) immunotherapy (stage IIIA, B, & C disease, p<0.0001), and (D) radiotherapy (stage IIIA, B & C disease p≤0.03) by age. Chemotherapy included BRAF/MEK inhibitor therapies.